{
  "id": "enwiki-001375574978",
  "slug": "2c-b",
  "title": "2C-B",
  "qid": "",
  "lead": "2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families. The drug is used as a recreational drug and is usually taken orally. 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects. Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin. The drug acts as a potent partial agonist of the serotonin 5-HT 2 receptors, including of the serotonin 5-HT 2A receptor. It produces psychedelic-like effects in animals. Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others. 2C-B was developed by Alexander Shulgin in 1974 and was described by him in the scientific literature in 1975. The drug emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s. Subsequently, it became a controlled substance in the United States in the mid-1990s. 2C-B was one of the first 2C psychedelics to be described. It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs.",
  "body": "2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families. The drug is used as a recreational drug and is usually taken orally. 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects. Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin. The drug acts as a potent partial agonist of the serotonin 5-HT 2 receptors, including of the serotonin 5-HT 2A receptor. It produces psychedelic-like effects in animals. Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others. 2C-B was developed by Alexander Shulgin in 1974 and was described by him in the scientific literature in 1975. The drug emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s. Subsequently, it became a controlled substance in the United States in the mid-1990s. 2C-B was one of the first 2C psychedelics to be described. It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs. 2C-B acts as a potent partial agonist of the serotonin 5-HT 2 receptors, including of the serotonin 5-HT 2A and 5-HT 2C receptors and to a lesser extent of the serotonin 5-HT 2B receptor. In one study, it had ( ) values of 1.2 nM (101%) at the serotonin 5-HT 2A receptor, 13 nM (97%) at the serotonin 5-HT 2B receptor, and 0.63 nM (98%) at the serotonin 5-HT 2C receptor. In earlier studies, 2C-B was found to be a low-efficacy serotonin 5-HT 2A and 5-HT 2C receptor partial agonist or even antagonist. However, subsequent studies have consistently found higher efficacy of 2C-B at these receptors. In addition to the serotonin 5-HT 2 receptors, 2C-B also shows lower affinity for other serotonin receptors, such as the serotonin 5-HT 1A and 5-HT 1B receptors among others. However, while 2C-B itself was not assessed, other 2C derivatives showed little activity as serotonin 5-HT 1A receptor agonists ( = >3,000 nM). At the serotonin 5-HT 2A receptor, 2C-B has subsequently been identified as a biased agonist, acting as a near-full agonist of receptor in terms of Ca 2+ mobilization ( = 1.64 nM; = 92.6%) but with 6-fold lower potency as a moderate-efficacy partial agonist in terms of β-arrestin2 recruitment ( = 10.0 nM; = 60.1%). However, serotonin itself showed about 42-fold greater potency in activating Ca 2+ mobilization than β-arrestin2 signaling in the study. The implications of the preceding findings are not fully clear. 2C-B has been reported to be an allosteric or non-competitive serotonin transporter (SERT) inhibitor or serotonin reuptake inhibitor, albeit of very low potency. Although 2C-B itself was not evaluated, other closely related members of the 2C series, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2, all showed no activity as monoamine releasing agents of serotonin, norepinephrine, or dopamine ( = >100,000 nM or \"inactive\"). 2C-B shows dopaminergic actions mediated by the dopamine transporter (DAT) in monkeys but not in rodents. 2C-B produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It shows reinforcing effects in monkeys but not in rodents. The drug also shows potent and efficacious anti-inflammatory effects in preclinical research. In contrast to MDMA, which robustly increases oxytocin levels and produces associated entactogenic effects, 2C-B minimally affects oxytocin levels in humans. 2C-B - The Shulgin Index The Big & Dandy 2C-B Thread - Bluelight Molecular Memoirs: 2C-B, The \"Warm Hug\" - The Shulgin Foundation 2C-B, the Forgotten Psychedelic: Understanding the \"Love Child\" of Alexander and Ann Shulgin - Psychedelics.com Forgotten Psychedelics: What Is 2C-B? - Psychedelic Spotlight Is 2C-B a Psychedelic Drug? - Psychedelic Science Review (PSR) 2C-B: Effects, Dosage, & Safety - Tripsitter 2C-B - TripSit 2C-B – Graceful, Erotic, and Sensual? - HealingMaps 2C-B: If LSD and MDMA had a baby - PsychedelicHealth 2C-B Is the Drug Taking Over the UK's Clubs - Vice",
  "categories": [
    "10639558",
    "109594295",
    "114779521",
    "114951262",
    "20199460",
    "23118434",
    "23603337",
    "24745122",
    "27020700",
    "27236659",
    "27923982",
    "29082335",
    "39185684",
    "43371251",
    "44053684",
    "50769796",
    "51480462",
    "62929564",
    "63697623",
    "63713762",
    "63715446",
    "63716185",
    "64663921",
    "65121943",
    "65121944",
    "65121945",
    "67819591",
    "8135464",
    "89061603",
    "90256262"
  ],
  "license": "CC BY-SA 4.0",
  "source_uri": "https://en.wikipedia.org/w/index.php?oldid=1375574978",
  "content_hash": "",
  "created_at": null,
  "updated_at": 1789743465.0,
  "claims": [],
  "contradictions": [],
  "confidence": 0.6,
  "csl": {
    "id": "enwiki-001375574978",
    "type": "webpage",
    "title": "2C-B",
    "author": [
      {
        "family": "Anticloud FZ LLE",
        "literal": "Anticloud FZ LLE"
      }
    ],
    "container-title": "encyclopegia.org",
    "publisher": "Anticloud FZ LLE",
    "publisher-place": "Dubai, United Arab Emirates",
    "URL": "https://encyclopegia.org/a/2c-b",
    "issued": {
      "date-parts": [
        [
          2026,
          11,
          18
        ]
      ]
    },
    "accessed": {
      "date-parts": [
        [
          2026,
          11,
          18
        ]
      ]
    },
    "license": "CC BY-SA 4.0",
    "DOI": "eo1:enwiki-001375574978",
    "isBasedOn": "https://en.wikipedia.org/w/index.php?oldid=1375574978",
    "note": "Immutable snapshot enwiki-001375574978"
  }
}